List of Implants Companies with Phase 4 Active Clinical Trial - 115

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it has a broad network of distributors in more than 20 countries at the international level. aap Implantate AG is a stock listed company. Its share is quoted in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). .

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com. Important Safety Info: https://bit.ly/39kvb47

Acandis GmbH is a medical technology company based in Pforzheim, Germany, founded in 2006. It focuses on developing, manufacturing, and marketing products for the treatment of neurovascular diseases, particularly in acute and preventive stroke treatment. The company is recognized for its innovative approach and has been named one of the TOP 100 most innovative SMEs in Germany multiple times. Acandis offers a variety of high-tech medical devices, including thrombectomy devices for removing blood clots, embolisation devices to block abnormal blood flow, stents to keep arteries open, and catheter systems for minimally invasive procedures. These products are developed in collaboration with healthcare professionals to ensure they meet clinical needs effectively. With a dedicated team of around 107 employees, Acandis aims to expand its reach internationally, providing essential tools for stroke prevention and therapy to endovascular specialists.

Adient Medical is a medical devices company that specializes in absorbable devices that automatically vanish, eliminating the need for removal procedures.

AB is proud to be the only U.S. based manufacturer of cochlear implants and equally proud to be a part of the larger Sonova group. At AB, success begins with a passion for hearing restoration and is driven by our global workforce of over a thousand employees. For more than 25 years, AB has removed limitations for those otherwise isolated from the world of sound. Always focused on bringing meaningful change through innovative technology, AB has set the standard for performance, lifestyle support, and access to sound in the field of cochlear implantation. Having implanted over 100,000 ears in over 130 countries and established a track record for developing high-performing, state-of-the-art products, our team of talented scientists, engineers, audiologists and other professionals are driven to succeed, work with integrity, and stay firmly committed to quality. Sonova companies include brands focused on hearing aids, cochlear implants, wireless communications, and clinical service. Together, we strive to create a world where everyone enjoys the delight of hearing and lives a life without limitations.Advanced Bionics is a global leader providing solutions for severe-to-profound hearing loss.

Alleviant Medical is a medical device company developing next-generation therapies for heart failure.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we're dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix's Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Anteris Technologies is a structural heart company focused on developing innovative solutions to the biggest challenges facing aortic stenosis patients and their physicians. Our DurAVR™ Transcatheter Heart Valve (THV) System is designed for younger patients who need a heart valve that will last their lifetime. DurAVR™ THV is a unique, single-piece valve and its first-in-class biomimetic design replicates the normal blood flow of a healthy human aortic valve. | $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology

Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves, and aortic stents and stent-grafts. Artivion has over 1,250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta, Georgia, Austin, Texas, and Hechingen, Germany. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America.

Atreon Orthopedics is a tissue regeneration company powered by breakthrough regenerative technology and renowned scientific expertise. Tendon and ligament injuries affect ten million people yearly, spanning all lifestyles and demographics. Atreon is committed to dramatically improving healing and long-term outcomes for patients encountering these soft-tissue injuries. ROTIUM®, our initial product for rotator cuff repair, is a bioresorbable wick designed as a scaffold to harness and hold biologically active substances at the repair site providing a pro-healing environment that promotes healthy tissue and native tissue regeneration. Recently published human and animal studies and over 10,000 cases have shown a safe and effective solution to improving biology, restoring function, and improving rotator cuff success rates.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years. More information can be found on www.atromedical.com

Aurora specializes in minimally invasive, regenerative technologies. It is our vision to be the leader in advanced spinal technologies which will impact lives worldwide. Based in Carlsbad, California we design, develop and manufacture quality spinal implants to be sold worldwide.

Developing seamless neural interfaces.

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

BioPoly® was established to provide a treatment option for painful cartilage lesions between the extremes of biological solutions and total joint replacement. Utilizing a patented material that is self-lubricating for improved wear properties (via a biological enhancement with Hyaluronic Acid) the BioPoly® RS devices are uniquely designed to replace only the damaged cartilage. Therefore, patients can quickly recover and return to pain-free, active lifestyles. BioPoly® RS devices are currently available for femoral condyle, trochlear facets, trochlear groove, patella, and humeral head applications. Patients out to >10 years have experienced a significant reduction in pain and have shown improved quality of life. Additional orthopedic applications are currently in development. BioPoly® serves healthcare professionals and their patients throughout the world from our headquarters in Fort Wayne, Indiana, USA.

Bioretec Ltd. is a medical device company focusing on the development of strong, safe and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. Our products are used worldwide, and we continue to further develop materials and products for load-bearing clinical applications.

BiVACOR is a medical technology company that specializes in developing advanced artificial heart solutions.

BlueWind Medical is a medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has successfully completed several clinical studies and is focused on bringing this breakthroughRENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Cadence Neuroscience is developing a fundamentally new approach to neuromodulation, starting with a therapy to treate severe epilepsy.

Cagent Vascular (Wayne, PA) has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology

Caldera Medical is a medical device company solely focused on women's health with a commitment to our mission of "Improving the Quality of Life for Women!" We develop, build and market best in class surgical products for the treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse. Working closely with surgeons to help those here at home, as well as women around the world, through our humanitarian programs to give them the access to the education and treatment they deserve. Mission - To Improve the Quality of Life for Women Vision - To be the Global Leader in Women's Pelvic Health Values "C4"​ - Care / Collaborate / Challenge / Create

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Cardiac Dimensions is reimagining the solutions available to patients suffering from heart failure (HF) by providing a therapy which allows patients to live longer, higher quality lives. Our product, the Carillon Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat patients with mitral valve insufficiency in a safe and effective manner. The Carillon therapy is the only indirect, no-touch mitral valve repair option designed to produce an annuloplasty effect while initiating left ventricular remodeling and improving long-term survival for patients. The Carillon therapy can also be used alongside other HF treatments should they be needed. Learn more about this proven solution for HF patients that uniquely treats the underlying causes—not symptoms—of mitral insufficiency at the website link below.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

CereVasc, Inc. is a clinical-stage, medical device company developing novel treatments for neurological diseases. The company is focused on developing the eShunt™ System for the treatment of patients with hydrocephalus. CereVasc aims to improve patient outcomes and redefine the treatment of communicating hydrocephalus through its innovative medical devices.

CivaTech Oncology® designs innovative products that bring meaningful improvements to low dose rate brachytherapy. The CivaString® and CivaSheet™ can substantially reduce procedure time, provide homogeneous dose distribution and minimize trauma. Customizable CivaTech products ensure that radiation oncologists can deliver individualized, targeted therapy to treat cancer. http://www.civatechoncology.com/

Hear now. And always As the global leader in implantable hearing solutions, at Cochlear (ASX: COH) we are committed to our mission to help people hear and be heard. Our story started more than four decades ago when Professor Graeme Clark pioneered the world's first multi-channel cochlear implant and created an entirely new treatment for hearing loss. Since our formation in 1981, we continue Professor Clark’s work to help people with moderate to profound hearing loss experience a life full of hearing. We have provided more than 650,000 implantable devices. Each recipient helps form a global community of millions, through families, friends, colleagues, teachers and more. And they’re not just connected to their own community — each shares a link with each other and to Professor Clark’s childhood desire to help people hear. We aim to give people the best lifelong hearing experience and access to innovative future technologies. We understand the privilege of connecting people to a life lived with hearing. And we listen, respond and move with the times – to continue to bring hearing within reach of all those who need it. That's how we live our mission every day. Our global workforce of more than 4,000 people shares a collective determination to give more people the opportunity to enjoy a life of hearing. Cochlear’s global headquarters are on the campus of Macquarie University in Sydney, Australia with regional headquarters in Asia Pacific, Europe and the Americas. Through our offices in over 180 countries we help people of all ages to hear. Social Media Terms of Use http://bit.ly/2qRMEvY

Concept Medical Inc. is a Research-oriented organization. It is into the development of a novel drug-eluting balloon catheter (DEB) using the latest Nano Technology. Aim of CMI is to develop innovative and revolutionary medical devices for the treatment of Cardiovascular Diseases. Concept Medical Inc. was incorporated on June 2008 in Cleveland OH. Later on, the company moved to San Jose, California. Currently, the company has a Business Development office with its Main Research Unit located at Surat, India. Concept Medical Inc. has set up a full-fledged research center which is involved in the development of Nanocarrier based drug delivery technology. Its team of Scientists and Engineers hold International Patents on research. Concept Medical Research Pvt. Ltd. has featured on Indian Government's list of top ten companies in the Pharmaceutical sector for its research in Medical Device technology. Our core development areas and offerings include drug delivery technologies comprising of various types of coatings, nanoparticles, and nanocarrier delivery systems, and coatings that have pro healing properties, and biocompatibility capabilities. Our strategy is to build on our strong technical leadership in the field of Nano carrier-based drug delivery and products, visioning to strengthen our position as an innovative and resourceful product development partner to the Medical Device industry.

Cordis is a medical devices company that specializes in cardiology equipment and healthcare technology.

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.

Cryosa is a clinical stage company developing a treatment for moderate to severe Obstructive Sleep Apnea (OSA). We believe that mask-free, hose-free, implant-free treatment is possible. Everyone is free to sleep, free to rest and free to live brighter days.

CryoTherapeutics is a company that focuses on developing cryotherapy systems for the treatment of heart attacks in Europe and the USA.

CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body's own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

Empirical Spine, Inc., is focused on developing disruptive solutions for the surgical treatment of spinal disorders, in order to deliver superior clinical outcomes while lowering overall healthcare costs. We are building a new standard in spine surgery that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life by creating a new category called Dynamic Sagittal TetherTM (DST). For patients with mobile degenerative spondylolisthesis, LimiFlexTM is the first and only Dynamic Sagittal Tether that restores the natural motion and stability required after a decompression by augmenting the posterior tension band, creating elastic resistance to flexion and maintaining lordosis, and offers the potential for significant reduction in cost, invasiveness, and sequelae compared to spinal fusion. The U.S. pivotal trial on our breakthrough LimiFlex Dynamic Sagittal Tether is fully enrolled and nearing its two-year endpoint. In summer 2022, we expect to submit results from this trial to the FDA for PMA approval. Follow our LinkedIn page for company news and updates. For more information about LimiFlex Dynamic Sagittal Tether visit the following website: https://www.limiflex.com/. Caution: The LimiFlex DST is an investigational device in the U.S. and is limited by law to investigational use.

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. We have a therapeutic portfolio designed to treat diseases which currently have clinically relevant unmet needs. Our existing products can treat a wide spectrum of vascular disease through abdominal aortic aneurysms to lower limb peripheral vascular disease. We obtain excellent clinical outcomes through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. With a robust pipeline of disruptive technology, our vision is to provide physicians with the best device for each patient; because when it comes to ensuring patient well-being, we are never satisfied with the status quo.

The NEXUS® Aortic Arch Stent Graft System by Endospan is the only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS® is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS® "Dock and Lock" modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan's NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.

Enovis is a data analytics company that provides technology solutions for business intelligence and information management.

Envoy Medical (Nasdaq: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Exactech is a global medical technology company that empowers orthopaedic surgeons with innovative implants, surgical instruments and the Active Intelligence® (AI) ecosystem of smart technologies to give patients EXACTLY what they need to regain mobility. Visit www.exac.com for more information. Exactech will never ask you to conduct an interview via text message. We value your privacy and do not ask applicants for financial information or ask applicants to make any purchases. If you believe that you have been contacted by a cybercriminal, please contact your local police department.

Our Vision: To revolutionize the structural heart market with new material, design and manufacturing technology expanding patient access, improving product performance and significantly reducing costs.

At Glucotrack, we are pioneers in diabetes technology, dedicated to transforming the way diabetes is managed. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. With a commitment to reducing the daily burden of diabetes management, we create cutting-edge technologies designed to enhance the lives of those we serve. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering.

Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.

IGENOMIX USA is a biotechnology company that specializes in genetic testing services for reproductive health and fertility.

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM. The Optimizer Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS durations.

Inbrain Neuroelectronics is a Neuroelectronics company that specializes in high density and high resolution graphene intelligent neural systems for central and peripheral neuroelectronic applications, with FDA breakthrough Designation.

InnovHeart, with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The company is currently in clinical trials testing its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery. Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. InnovHeart is committed to pursuing this goal with the highest level of quality.

inQB8 is a med-tech incubator founded in 2018 to develop novel, device-based solutions for the biggest cardiovascular challenges and create successful start-ups that can bring those solutions to the patients that need them most.

InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) designed for delivering neurovascular protection and stroke prevention. InspireMD is dedicated to the development of advanced technologies and seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes through a proprietary stent platform, CGuard™ EPS. CGuard brings to the world the only carotid stent platform with patented MicroNet™ mesh technology designed to reduce stroke during and after CAS. InspireMD (NSPR) is traded on NASDQ Capital Markets.

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use

Jarvik Heart Inc. is a developer and manufacturer of life sustaining miniaturized cardiac (heart) assist devices, founded by Dr. Robert Jarvik, the inventor of the first permanent total artificial heart.

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.

KiOmed Pharma is a biotechnology company based in Belgium that focuses on developing, manufacturing, and distributing chitosan-based medical devices. The company, a spinout from KitoZyme, utilizes exclusive natural chitosan chemistry to create solutions for high-impact medical conditions, particularly in osteoarthritis, dermatology, and ophthalmology. Headquartered in Herstal, Liège, KiOmed Pharma emphasizes therapeutic innovations through its proprietary KiOmedine® technology platform. One of its key products is KioMedine(vs)one, a single-injection soft implant designed to relieve pain and improve mobility in knee osteoarthritis patients. The company is also developing additional products targeting joint health, skin aging, and eye-related disorders. KiOmed Pharma maintains a commitment to biocompatibility and safety by using non-animal-derived chitosan in its formulations. In April 2024, KiOmed Pharma formed a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to its treatments while generating revenue through royalties and milestone payments. Under the leadership of CEO Houtaï Choumane, the company aims to create long-term value and improve patient outcomes in chronic diseases.

Laborie is a world-class specialist medical company that makes and advances technologies that preserve and restore human dignity. We take great pride in supporting doctors, nurses, hospitals, clinics, academic institutions and patients with treatment and diagnostic innovations. Our technologies include diagnostic equipment and consumable supplies in the Urology, Gastroenterology, Gynecology, Obstetrics and Neonatology fields. Privately owned by Patricia Industries and a part of the Investor AB network, Laborie is comprised of powerful brands that have been cultivated for more than 50 years. As a rapidly growing and scaling organization, our company values drive our day-to-day behaviors and make us ONE Laborie whenever and wherever we do business. We know that the work we do matters and we’re making a positive impact in the lives of patients across the globe. This is what fuels our motivation each day. If you’re ready to be part of a mission with meaning and a rewarding environment with opportunities for professional growth and career advancement, view our current job openings at https://laborie.bamboohr.com/jobs/ and apply online.

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN." LivaNova has approximately 2,900 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Loci Orthopaedics develops innovative orthopaedics medical technologies to meet large unmet clinical needs.

Magenta is developing miniaturized catheter-mounted axial flow-pumps for mechanical circulatory support indications, based on Magenta's core technology of self-expanding impellers and pump heads. Our percutaneous Left Ventricular Assist Device (pLVAD) is a next-generation low-profile arterial pump, intended for temporary support of patients undergoing high-risk coronary interventions and the treatment of patients admitted with cardiogenic shock.

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 50 countries.

Medtronic plc is an Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Dublin, Ireland. Medtronic operates in more than 140 countries and employs over 90,000 people worldwide. The company is the world's largest standalone medical technology development company.

Melodi Health offers novel technologies that improve patient outcomes for women undergoing breast surgery. Melodi Health manufactures the Melodi Matrix, designed to support the soft tissue space around a prosthetic device while delivering antibiotics to the surrounding tissue. The Melodi Matrix is currently an investigational device being studied in a prospective, multi-center, randomized, controlled clinical trial in breast reconstruction.

Meril's core objective is to design, manufacture and distribute clinically relevant, state-of-the-art and best-in-class medical devices to alleviate human suffering and improve quality of life. We thus have a strong commitment towards R & D and adherence to best quality standards in Manufacturing, Scientific Communication and Distribution known today. Origin Established in 2006, Meril was launched in line with the health-care diversification plan by a large format Indian multi-national company. Disclaimer: Information on Meril Digital / Social Media platform is not intended to be a substitute for professional medical advice, diagnosis or treatment. Meril does not recommend self-management of health issues. For more information, visit: https://www.merillife.com/disclaimer

As a global healthcare company, we understand customer needs and innovate and deliver medical solutions that transform patient care. Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.

Developer of bio-engineered surgical implants designed to facilitate new tissue growth and also aid in connective tissue repair. The company's implants specialize in viable alternatives to conventional ACL reconstruction for patients who have sustained any kind of leg injury, enabling surgeons to perform surgery to restore normal anatomy and function of the knee.

Miracor Medical SA is a European medical device company dedicated to improve clinical outcome of patients with impaired cardiac function. Miracor develops and studies the PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) Impulse System, which is used as an adjunctive technique during the primary PCI procedure for acute myocardial infarction patients. PiCSO therapy seeks to improve coronary microvascular function to reduce infarct size and salvage myocardium, thereby improving outcomes of ST-elevation myocardial infarction (STEMI) patients. Recent Clinical Studies have successfully demonstrated the safety and positive effects of PiCSO on coronary microvascular function and infarct size reduction in STEMi patients. The company is conducting further clinical trials in Europe and plans to initiate a US IDE randomized controlled trial in 2023. Miracor has won several innovation awards and completed financing rounds raising venture capital and public funding. The company was founded in May 2008 by Professor Dr. Dr. Werner Mohl and the European venture capital firms Earlybird and Delta Partners.

Implantable Shock Absorbers for Knee OA

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera's minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Building Brain Computers Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca'​ Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics and biotechnologies.

Novostia is a privately held medical device company developing an innovative artificial heart valve, designed for patients of any age, including children. Novostia endeavors to advance its technology to clinical trials and regulatory approvals to improve the quality of life of millions of people worldwide suffering from aortic and mitral valve disease. For more information please visite www.novostia.com

Nyxoah is a pioneering medical device company developing a breakthrough therapeutic solution for the treatment of Obstructive Sleep Apnea (OSA). Our mission is to become a world leading company by offering unique patient-centric neuromodulation solutions, developed by passionate and exceptionally driven people Nyxoah's therapy Genio® offers: - Unparalleled clinical efficacy - Increased patient comfort, therapy compliance and quality of life - Minimally invasive approach, thus streamlining patient flow and reducing surgery related risks - Positive health economics outcomes by reducing the burden of OSA and its comorbidities

Ophtec is a family-owned company founded in 1983 by Prof. Dr. Jan Worst and Anneke Worst-Van Dam. Based in the Netherlands, it is a global leader in intraocular lens (IOL) innovation, specializing in solutions for cataract and refractive surgery. With a focus on pioneering ophthalmic products, Ophtec has recently modernized its brand while celebrating 40 years of excellence in the field. The company offers a range of products, including monofocal, toric, and presbyopia-correcting cataract IOLs, as well as the Artisan lens, the first iris-fixated IOL for refractive correction. Ophtec is also developing new innovations, such as the ArtiPlus lens and pre-loaded injector systems. In addition to its product offerings, Ophtec provides surgeon training and clinical support, collaborating with ophthalmologists to enhance surgical techniques and outcomes. The company is dedicated to empowering eye surgeons to deliver high-quality vision results, particularly in complex cases.

Orchestra BioMed biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine.

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. 𝗢𝘂𝗿 𝗩𝗶𝘀𝗶𝗼𝗻: To be the unrivaled partner in MedTech, delivering exceptional experiences and life-changing solutions. 𝗢𝘂𝗿 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: We provide medical technologies that heal musculoskeletal pathologies. We enable our teams through opportunities for growth, ownership of responsibilities, and empowerment to execute. We do this for patients and the healthcare professionals who treat them. We collaborate with world-class surgeons and other partners to bring to market highly innovative, cost-effective, and user-friendly medical technologies through excellent customer service. We do this to improve people’s quality of life and, in doing so, create exceptional value for our customers, employees, and stockholders. 𝗢𝘂𝗿 𝗩𝗮𝗹𝘂𝗲𝘀: • Take Ownership • Innovate Boldly • Win Together Join our mission to revolutionize musculoskeletal care and be a part of innovation that changes lives. Start your journey now at https://orthofix.com/about/careers/.

OrthoPediatrics is an Indiana-based bio-science company that designs and develops orthopedic implants and instruments for pediatric conditions.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)

Paragon 28 was established in 2010 as an orthopedic foot and ankle company. The name "Paragon 28" was chosen to show that we are exclusively a foot and ankle company, with the "28" representing the number of bones in the foot. We will remain true to that vision. Paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. Our mission is to strategically build a company around the core principles that drive innovation and quality. Relentlessly working to advance the science behind foot and ankle surgery, Paragon 28 is passionate about and committed to: - Creation and Innovation: Blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - A Focus on Service: A customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - Efficient Practices: Meeting the needs of increasing pricing pressures and reimbursement while continuing to develop cutting-edge surgical implants. - Practical and Comprehensive Solutions: Creating complete surgeon-centric systems, specialty instruments, and next generation implants to solve real world issues faced by foot and ankle surgeons. - Research Motivated: Improving clinical outcomes through meaningful and unbiased research. We are ready to embrace research data regardless of marketing impact. Motivation, competition and the desire to learn are unique characteristics that are incredibly valuable to our success. Paragon 28's work environment is modern and exciting. We are seeking experienced and energetic individuals to join our team in areas of Quality, Engineering, Marketing, Sales, Administration and Accounting.

Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCut™ is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access.

ProVerum Medical is a Dublin-based medical device company founded in 2016. The company specializes in minimally invasive solutions for benign prostatic hyperplasia (BPH), focusing on developing technologies that address lower urinary tract symptoms caused by prostate enlargement. Their primary product, the ProVee System, features a nitinol expander designed to reshape the enlarged prostate and alleviate urinary obstruction. This system is deployed through a low-profile, flexible delivery method that integrates imaging, making it compatible with standard office-based endoscopes. The procedure is minimally invasive and can be performed under local anesthesia, offering a patient-friendly alternative to traditional surgery. ProVerum holds eight patents, including one granted in 2023 for a device that deploys expandable implants targeting BPH and urinary system disorders. The company has raised a total of $38.58 million in funding, including a €30 million Series A round in 2022. ProVerum is currently conducting the ProVIDE study to evaluate the safety and efficacy of the ProVee system, which completed enrollment in March 2024.

R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD is the narrowing or blockage of the vessels that carry blood from the heart to the legs or lower extremities; it is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can happen in any blood vessel, but it is more common in the legs than the arms. It affects 200 million people globally. Approximately 6.5 million people at the age of 40 and older in the United States have PAD. These numbers continue to rise given the increasing burden of risk factors and an aging population. If a patient has PAD, they are at risk for developing coronary artery disease and cerebrovascular disease, which could lead to a heart attack or stroke as well. The R3 Vascular BVS platform combines the best of both worlds of BTK therapy, designed to deliver the ‘stent-like' support of a scaffold, along with the anti-inflammatory result of sirolimus, but ‘disappearing' over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

RevBio was started with one goal in mind—to end medicine's 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm's secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

RTI Surgical (RTI) is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. We focus on specialized clinical segments, including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. Our Mission is to enhance patients' lives by creating the best clinical outcomes through innovative, high-quality medical solutions.

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM"​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

ShiraTronics is a forward-thinking medtech startup committed to revolutionizing the field of migraine medicine with our minimally invasive neuromodulation system. Our mission? To transform the lives of those facing Chronic Migraine by reducing headache days and restoring quality of life.

The simplicity of our design--born out of our extensive experience--comes down to the basic notion that traditional fixation techniques aren't strong enough and don't last. Our InSet™ approach to Glenoid fixation is revolutionizing shoulder arthroplasty and, more importantly, improving procedure longevity--ultimately changing patient's lives.

We are reimagining eyecare with transformative technology and an interventional mindset. We believe interventions should happen sooner to preserve, protect, or restore natural eye function. So, we aim to provide eyecare providers with transformative, clinically-proven therapies that are intuitive, less invasive, and more intelligent.

Spiderwortisdeveloping a novel biomaterial that will offer new avenues in 3D in vitro research and in regenerative medicineusing plant derived cellulose to create a variety of scaffold architectures.

Founded in 2003, Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

Spinal Stabilization Technologies, LTD ("SST") is a commercial-ready U.S. medical device company with a manufacturing facility in Ireland through its Irish subsidiary. The Company has developed a new surgical device and procedure for restoring the nucleus pulposus of the lumbar spine. The company has extensive worldwide intellectual property. The products and techniques SST develops are based on the philosophy that less invasive surgery may be associated with better clinical outcomes. These products and techniques could improve the lives of many patients that have limited options for treating their back pain. The company is focused on evidence-based medicine, has completed three trials, is currently conducting a clinical trial and is in the planning phase of two additional clinical trials.

Spineart is a privately held medical device company focused on accelerating technology adoption and elevating the standard of spinal care. As a global market leader in spine surgery, we support spine surgeons in over 60 markets worldwide and have introduced unique technologies in the field of minimally invasive surgery, motion preservation, fusion, biologics, fracture treatments, and more. Spineart offers a comprehensive portfolio of procedural solutions and technologies that combine traceable barcoded sterile-packed implants with compact instrument sets, ultimately promoting greater safety, cost-efficiency, and compliance for hospital systems worldwide. Spineart was awarded the "Prix de l'Economie Genevoise 2022" for its contribution to technological and scientific innovations, commercial activities, job creations and ESG principles. Join us as we continue to challenge convention, deliver global expertise, and empower superior care. See open positions at https://www.spineart.com/careers/ This profile is intended for global audiences. For US-specific updates follow our Spineart USA profile.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Synapse Biomedical Inc (SBI) was founded in September 2002 to commercialize the NeuRx Diaphragm Pacing System (DPS)® that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency. This innovation allows the technology to meet clinical needs, beyond the ability of the currently available systems, in Spinal Cord Injuries, in the diaphragm conditioning in muscular dystrophies (such as ALS) and in respiratory short-term intensive care settings.

Synchron is a Brain Computer Interface company based in Campbell, California and Melbourne, Australia. We are developing minimally-invasive technology for safe and rapid implantation of miniaturized electronic medical devices with broadband capability.

Delivering the latest innovation in sacroiliac joint surgical solutions, Tenon Medical is uniquely positioned to introduce a refined surgical option for patients with chronic sacroiliac joint pain that fail conservative care. The Catamaran™ SIJ Fusion System offers a patented new surgical solution that places a single implant directly into the SI joint. Tenon Medical is led by a powerful team with years of cumulative experience in designing and launching innovative surgical solutions that deliver a pathway to improved quality of life for thousands of patients.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

TRiCares GmbH is a medical device company based in Munich, Germany, with additional offices in Paris, the U.S., and Brazil. Founded in 2013, the company specializes in minimally invasive solutions for tricuspid regurgitation (TR), a serious heart valve condition affecting millions of patients. TRiCares focuses on transcatheter tricuspid valve replacement (TTVR) systems, aiming to meet the clinical need for non-surgical treatments. The flagship product, Topaz, is a transfemoral TTVR system designed for easy implantation via the femoral vein. It features a dual-stent design that accommodates anatomical variability and is suitable for high-risk patients, avoiding the need for open-heart surgery. TRiCares is actively conducting clinical trials in the U.S., Canada, and Europe to further validate the effectiveness of the Topaz system. Recently, the company raised $50 million in Series D financing to support its clinical milestones and expand its market presence.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

UroMems was founded in 2011 and focuses on designing, developing and commercializing active implantable medical devices. The company is based at the heart of the French Silicon Valley, in the Sophia Antipolis technopark, near Nice, France.

Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy. Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022. We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow. We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than 13,000 real-world implantations. As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.

The company develops advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery.

V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave's vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company's senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes Best-in-State Employers in Indiana (2020 and 2021) • Newsweek's America's Most Responsible Companies (2021) • Military Friendly Employer by VIQTORY (2019 and 2020) • Best Employer Award: China (2011-2021) • Great Place to Work: Brazil (2021) • Indiana Manufacturers Association Manufacturing Excellence Awards (2020) • ComputerWorld's "Best Places to Work in IT" (2018-2020) • Forbes Global 2000 (2020 and 2021) • Fortune 500 List (2020 and 2021) • Medical Device and Diagnostic Industry MedTech Company of the Year (2019)

ZimVie is a global leader in dental implants and spine innovations. Advancing clinical technology foundational to restoring daily life.